Loading...
In two recent studies of patients with asthma and gastroesophageal reflux disease (GERD), esomeprazole did not significantly improve asthma control (JW Gen Med Jun 6 2006 and Apr 16 2009). Now, in yet another trial, industry-sponsored researchers randomized 961 patients with asthma and symptomatic GERD to receive esomeprazole (40 mg either once or twice daily) or placebo.
At 26 weeks, neither of the two esomeprazole groups differed from the placebo group in the primary outcome, morning peak expiratory flow. Asthma symptom scores, numbers of asthma exacerbations, percentage of asthma-free days, and use of rescue bronchodilators were also similar in the esomeprazole and placebo groups. For several secondary outcomes, statistically significant …